Viatris CCO Corinne Le Goff Sells 7032 Shares for $71,590 on Sept 11
ByAinvest
Friday, Sep 12, 2025 6:07 pm ET1min read
TBPH--
Revenues for the second quarter totaled $26.2 million, which was a 83.2% increase year-over-year. This was driven by increased collaboration revenues from partner Viatris and licensing revenues. Specifically, revenues from the Viatris collaboration reached $18.7 million, up 31% year-over-year, and the company received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [1].
Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of almost 8% from the year-ago quarter. Selling, general, and administrative expenses (excluding share-based compensation) also increased by around 16.4% year-over-year to $12.8 million [1].
As of June 30, 2025, Theravance had $338.8 million in cash, cash equivalents, and marketable securities compared to $130.9 million as of March 31, 2025 [1].
The company reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses to be in the range of $32-$38 million, adjusted SG&A expenses to be between $50 million and $60 million, and share-based compensation expenses to be $18-$20 million. The company expects adjusted losses and cash burn in 2025 to be similar to 2024 levels [1].
Investors have been optimistic about the stock, with estimates trending upward and a VGM Score of A [1]. However, the stock has a Zacks Rank of #3 (Hold), suggesting an in-line return in the next few months [1].
In other news, Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff sold 7,032 shares at a price of $10.25 per share on September 11, 2025 [2]. This insider trading activity may indicate a shift in the company's outlook or a change in the executive's personal financial strategy.
VTRS--
Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff has recently sold 7,032 shares at a price of $10.25 per share on September 11, 2025.
Theravance Biopharma (TBPH) has seen a significant increase in its stock price following its most recent earnings report. Shares have added about 9.8% in the past month, outperforming the S&P 500 [1]. The company reported a narrower-than-expected adjusted net loss of 8 cents per share for the second quarter of 2025, compared to the Zacks Consensus Estimate of a 14-cent loss. This was an improvement over the year-ago quarter, where the company incurred an adjusted loss of 13 cents per share [1].Revenues for the second quarter totaled $26.2 million, which was a 83.2% increase year-over-year. This was driven by increased collaboration revenues from partner Viatris and licensing revenues. Specifically, revenues from the Viatris collaboration reached $18.7 million, up 31% year-over-year, and the company received a milestone payment of $7.5 million from Viatris following the approval of Yupelri in China [1].
Research and development expenses (excluding share-based compensation) totaled $9.5 million, an increase of almost 8% from the year-ago quarter. Selling, general, and administrative expenses (excluding share-based compensation) also increased by around 16.4% year-over-year to $12.8 million [1].
As of June 30, 2025, Theravance had $338.8 million in cash, cash equivalents, and marketable securities compared to $130.9 million as of March 31, 2025 [1].
The company reaffirmed its financial guidance for 2025, expecting adjusted R&D expenses to be in the range of $32-$38 million, adjusted SG&A expenses to be between $50 million and $60 million, and share-based compensation expenses to be $18-$20 million. The company expects adjusted losses and cash burn in 2025 to be similar to 2024 levels [1].
Investors have been optimistic about the stock, with estimates trending upward and a VGM Score of A [1]. However, the stock has a Zacks Rank of #3 (Hold), suggesting an in-line return in the next few months [1].
In other news, Viatris Inc. has announced that Chief Commercial Officer Corinne Le Goff sold 7,032 shares at a price of $10.25 per share on September 11, 2025 [2]. This insider trading activity may indicate a shift in the company's outlook or a change in the executive's personal financial strategy.
Stay ahead of the market.
Get curated U.S. market news, insights and key dates delivered to your inbox.
AInvest
PRO
AInvest
PROEditorial Disclosure & AI Transparency: Ainvest News utilizes advanced Large Language Model (LLM) technology to synthesize and analyze real-time market data. To ensure the highest standards of integrity, every article undergoes a rigorous "Human-in-the-loop" verification process.
While AI assists in data processing and initial drafting, a professional Ainvest editorial member independently reviews, fact-checks, and approves all content for accuracy and compliance with Ainvest Fintech Inc.’s editorial standards. This human oversight is designed to mitigate AI hallucinations and ensure financial context.
Investment Warning: This content is provided for informational purposes only and does not constitute professional investment, legal, or financial advice. Markets involve inherent risks. Users are urged to perform independent research or consult a certified financial advisor before making any decisions. Ainvest Fintech Inc. disclaims all liability for actions taken based on this information. Found an error?Report an Issue
ABOUT US
Our StoryNews AuthorsKnowledge BasePrivacy PolicyTerm of UseThird Party Brokerage DisclaimerAIME Terms of UseAInvest AI Risk DisclosuresCareersCONTACT US
Email: support@ainvest.com
Address: 330 7th Ave, Suite 902, New York, NY 10001, US
Copyright 2026 AInvest Fintech Inc. All rights reserved.
Comments
No comments yet